HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysisGuillermo Villacampa, Sara M. Tolaney, José Manuel Pérez-García et al.|The Lancet Oncology|2025Cited by 20
Abstract P3-01-04: A real-world evidence study of everolimus plus endocrine therapy beyond CDK4/6 inhibitors for HR+/HER2- advanced breast cancerRodrigo Sánchez-Bayona, Eva Ciruelos, Manuel Alva et al.|Cancer Research|2023Cited by 1